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Abstract
The discovery of the receptor activator of nuclear factor-κB ligand
(RANKL)/RANK/osteoprotegerin (OPG) system and its role in the
regulation of bone resorption exemplifies how both serendipity and
a logic-based approach can identify factors that regulate cell
function. Before this discovery in the mid to late 1990s, it had long
been recognized that osteoclast formation was regulated by
factors expressed by osteoblast/stromal cells, but it had not been
anticipated that members of the tumor necrosis factor superfamily
of ligands and receptors would be involved or that the factors
involved would have extensive functions beyond bone remodeling.
RANKL/RANK signaling regulates the formation of multinucleated
osteoclasts from their precursors as well as their activation and
survival in normal bone remodeling and in a variety of pathologic
conditions. OPG protects the skeleton from excessive bone
resorption by binding to RANKL and preventing it from binding to
its receptor, RANK. Thus, RANKL/OPG ratio is an important
determinant of bone mass and skeletal integrity. Genetic studies in
mice indicate that RANKL/RANK signaling is also required for
lymph node formation and mammary gland lactational hyperplasia,
and that OPG also protects arteries from medial calcification.
Thus, these tumor necrosis factor superfamily members have
important functions outside bone. Although our understanding of
the mechanisms whereby they regulate osteoclast formation has
advanced rapidly during the past 10 years, many questions remain
about their roles in health and disease. Here we review our current
understanding of the role of the RANKL/RANK/OPG system in
bone and other tissues.
Introduction
Bone serves multiple functions in vertebrates, including
support for muscles, protection of vital organs and hemato-
poietic marrow, and storage and release of vital ions, such as
calcium. Unlike other durable structures, such as teeth,
tendons, and cartilage, bone is continuously renewed by the
process of bone remodeling in which pockets or trenches of
bone are removed from the surfaces of trabecular and
cortical bone by osteoclasts and subsequently replaced by
new bone laid down by osteoblasts. There are at least one
million of these microscopic remodeling foci at any one time
in the adult skeleton, and the main function of this process is
considered to be removal of effete or worn out parts of bones
that have become damaged as part of normal wear and tear.
It is a highly regulated process, but the molecular mechanisms
that control its initiation, progression, and cessation at any
given site remain poorly understood.
Bone remodeling becomes perturbed in a variety of patho-
logic conditions that affect the skeleton, including post-
menopausal osteoporosis and rheumatoid arthritis, in which
there is local and/or systemic alteration in the levels of
hormones or proinflammatory cytokines that are known to
stimulate or inhibit bone resorption in vitro and in vivo. It has
been recognized since the early 1980s, when Rodan and
Martin [1] postulated that osteoblasts regulate osteoclast
formation, that factors expressed by osteoblasts within bone
are produced in response to known stimulators of bone
resorption, such as parathyroid hormone (PTH). Study of
bones from genetically altered mice and from animal models
of bone diseases during the past 10 years has greatly
increased our knowledge of the factors that regulate the
formation and activity of osteoclasts. In particular, identifi-
cation in the mid to late 1990s of the receptor activator of
nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin
(OPG) signaling system provided a major breakthrough that
clarified the role played by osteoblasts in these processes.
More recently, it has become increasingly clear that
osteoclasts are not simply trench digging cells, but that they
have important regulatory functions as immunomodulators in
pathologic states and that they may also regulate osteoblast
function [2].
Regulation of osteoclast formation and
activation
Osteoclasts are multinucleated bone resorbing cells formed
by cytoplasmic fusion of their mononuclear precursors, which
are in the myeloid lineage of hematopoietic cells that also
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give rise to macrophages. The switch to osteoclast
differentiation requires expression in osteoclast precursors
(OCPs) of c-Fos, a RANKL activated transcription factor [3].
To resorb bone effectively, osteoclasts attach themselves
firmly to the bone surface using specialized actin-rich
podosomes, which they use to form tightly sealed roughly
circular extensions of their cytoplasm with the underlying
bone matrix. Within these sealed zones they form ruffled
membranes that increase the surface area of the cell
membrane for secretion of hydrochloric acid and the
proteolytic enzyme cathepsin K onto the bone surface [4].
They thereby simultaneously dissolve the mineral and
degrade the matrix of bone, while protecting neighboring
cells from harm by this sealing mechanism. They are activated
by RANKL and by integrin-mediated signaling from bone
matrix itself [4]. Osteoclasts work in packs within remodeling
units under the control of osteoblast lineage cells expressing
macrophage colony-stimulating factor (M-CSF) and RANKL.
Recent studies of the mechanisms by which PTH exerts its
anabolic effects have suggested that osteoclasts are probably
involved in the recruitment of packs of bone-forming
osteoblasts to refill the trenches that they form on the bone
surface [2]. This is based on studies showing that, after PTH
injection, RANKL expression is increased by osteoblast/
stromal cells, leading to activation of existing osteoclasts and
release by them of a factor(s) that stimulates new bone
formation. Also, antiresorptive treatment, at least in some
studies, appears to reduce rather than enhance the anabolic
action of PTH [5-7]. As is discussed below, osteoclasts also
appear to regulate immune responses and their own produc-
tion at sites of inflammation in bone, such as rheumatoid joints.
Osteoclasts are required during embryonic development for
the removal of bone trabeculae formed under growth plates
during endochondral ossification and thus for formation of the
bone marrow cavity to facilitate normal hematopoiesis. Failure
of osteoclast formation or activity results in osteopetrosis,
some forms of which are lethal because of attendant immuno-
deficiency and increased risk for infection and recurrent
fractures. Indeed, the development of osteopetrosis in a
variety of knockout mice has identified necessary functions of
genes in osteoclast biology that largely had not been
anticipated [3,4].
Our understanding of the molecular mechanisms that
regulate osteoclast formation and activation has advanced
rapidly during the past 10 years since the discovery of the
RANKL/RANK signaling system, and following the
development in the late 1980s of in vitro assays that
facilitated harvesting of large numbers of OCPs from bone
marrow or spleen cells, which could then be cultured in the
absence of osteoblast/stromal cells. The strategy for acquiring
OCPs from these sources was developed in the knowledge
that M-CSF expression by osteoblast/stromal cells was
required for progenitor cells to differentiate into osteoclasts,
but that M-CSF on its own was unable to complete this
process. This requirement for M-CSF was based on the
observation that op/op mice, which do not express functional
M-CSF, have osteopetrosis because of a lack of osteoclasts
[3]. Indeed, since 1981, when Rodan and Martin [1] proposed
the novel hypothesis that osteoblast/stromal cells play a
central role in the regulation of osteoclast formation and bone
resorption, many investigators had attempted to identify the
osteoclast-activating factor that completed the differentiation
of precursors that had been exposed to M-CSF.
Discovery of osteoprotegerin, RANKL, and
RANK
Between 1981 and the mid 1990s, the Rodan–Martin
hypothesis was supported by many studies, but the factor(s)
expressed by osteoblast/stromal or other cells remained
undetermined until they were discovered independently by
four groups using different approaches.
Boyle and coworkers [8] at Amgen Inc. (Thousand Oaks, CA,
USA) discovered OPG unexpectedly in studies to identify
tumor necrosis factor (TNF) receptor related molecules with
possible therapeutic utility by generating transgenic mice that
over-express various TNF receptor related cDNAs. Mice over-
expressing one particular cDNA developed marked
osteopetrosis because they did not have any osteoclasts in
their bones. The protein encoded by the gene was named
osteoprotegerin (the bone protector) [8], because it
appeared to protect the skeleton from excessive bone
resorption by limiting osteoclastic bone resorption.
Independently, researchers at the Snow Brand Milk Products
Co. (Sapporo, Hokkaido, Japan) reported their discovery of
an identical molecule [9] using the standard approach to test
the Rodan–Martin hypothesis of purifying a factor from
human embryonic fibroblasts that inhibited osteoclastogenesis.
They obtained a partial protein sequence and subsequently
cloned the cDNA for OPG.
Using expression cloning and OPG as a probe, both groups
quickly identified its ligand, which they called OPG ligand
and osteoclast differentiation factor, respectively [10,11].
This ligand turned out to be identical to a member of the TNF
ligand family, which had been identified in the preceding year
as RANKL [12] and TNF-related activation induced cytokine
[13]. Soon after OPG ligand/osteoclast differentiation factor
was identified as a ligand for OPG, the cellular receptor was
identified as being identical to the previously identified RANK,
which Anderson and coworkers [12] at Immunex (Seattle,
WA, USA) had discovered while they were sequencing
cDNAs from a human bone marrow derived myeloid dendritic
cell cDNA library. They found that RANK had partial
homology to a portion of the extracellular domain of human
CD40, a member of the TNF receptor superfamily, and that it
was involved in the activation of T cells in the immune system.
They then isolated RANKL by direct expression screening
and found, like Wong and coworkers [13] did, that itPage 3 of 7
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increased dendritic cell stimulated naïve T cell proliferation
and survival of RANK-expressing T cells. These discoveries
that RANKL is involved in osteoclastogenesis and T cell
activation have spawned the now growing field of osteo-
immunology.
RANKL
RANKL is a type II homotrimeric transmembrane protein that
is expressed as a membrane-bound and a secreted protein,
which is derived from the membrane form as a result of either
proteolytic cleavage or alternative splicing [14]. The proteo-
lytic cleavage of RANKL requires ADAM (a disintegrin and
metalloprotease domain) [15] and matrix metalloproteases
[16]. RANKL expression is stimulated in osteoblast/stromal
cells by most of the factors that are known to stimulate
osteoclast formation and activity. It is highly expressed in
lymph nodes, thymus and lung, and at low levels in a variety
of other tissues including spleen and bone marrow [17]. In
inflamed joints it is expressed by synovial cells and secreted
by activated T cells. These sources of RANKL appear to be
responsible, at least in part, for mediating the joint destruction
in patients with rheumatoid arthritis [18]. TNF also mediates
joint destruction in rheumatoid arthritis by systemically
increasing the number of circulating OCPs, and by
promoting their egress from the bone marrow into the
peripheral blood and then to the inflamed joints, where it
promotes fusion of these cells to osteoclasts along with
RANKL and interleukin-1 [19].
RANKL, like TNF, stimulates the release of immature
progenitors into the circulation. However, RANKL does not
induce OCP mobilization in protein tyrosine phosphatase-ε
knockout mice with osteoclasts that are defective in terms of
bone adhesion and resorption [20]. Thus, RANKL-induced
osteoclast activation may regulate progenitor recruitment as
part of homeostasis and host defense, linking bone
remodeling with regulation of hematopoiesis. Preclinical
studies in mice have shown that RANKL is also expressed in
mammary epithelial cells during pregnancy and is required for
lactational hyperplasia of mammary epithelial cells and milk
production [21]. It is also expressed by some malignant tumor
cells that also express RANK, and thus it may play a role in
inducing tumor cell proliferation [22] by an autocrine
mechanism or in a paracrine manner if it is produced by
accessory cells, such as activated T cells. However,
production by T cells of RANKL also induces expression of
interferon-β by activated osteoclasts through c-Fos to
negatively regulate their formation [23]. This mechanism can
be enhanced by T-cell produced interferon-γ, which degrades
TNF receptor associated factor (TRAF)6, an essential
adapter protein that is recruited to RANK to mediate RANK
signaling (see below) [24].
RANK
RANK is a type I homotrimeric transmembrane protein whose
expression was initially detected only on OCPs, mature
osteoclasts, and dendritic cells. Like RANKL, however, it is
expressed widely [17]. RANK protein expression has been
reported in mammary gland [21] and some cancer cells,
including breast and prostate cancers [22,25], two types of
tumors with high bone metastasis potential. Although no
humans have been identified to date with inactivating
mutations or deletions of RANK, a deletion mutation occurred
spontaneously in a line of transgenic mice, which
consequently had all of the features of mice with targeted
deletion of RANK, confirming the importance of RANK for
osteoclast formation [26]. Activating mutations in exon 1 of
RANK that cause an increase in RANK-mediated nuclear
factor-κB (NF-κB) signaling and a resultant increase in osteo-
clast formation and activity account for the increased
osteolysis seen in some patients with familial Paget’s disease
and have confirmed the importance of this system in humans
[27]. A potential role for RANK in tumor cell proliferation [22]
is being investigated and, if proven, could be a future target
for anti-tumor therapy.
Osteoprotegerin
OPG is expressed in many tissues apart from osteoblasts,
including heart, kidney, liver, spleen, and bone marrow [17].
Its expression is regulated by most of the factors that induce
RANKL expression by osteoblasts. Although there are
contradictory data, in general upregulation of RANKL is
associated with downregulation of OPG, or at least lower
induction of OPG, such that the ratio of RANKL to OPG
changes in favor of osteoclastogenesis. Many reports have
supported the assertion that the RANKL/OPG ratio is a major
determinant of bone mass [28]. A osteoprotective role for
OPG in humans is supported by the report of homozygous
deletions of 100 kilobases of OPG in two patients with
juvenile Paget’s disease, an autosomal-recessive disorder
characterized by increased bone remodeling, osteopenia, and
fractures [29]. It is also supported by the identification of an
inactivating deletion in exon 3 of OPG in three siblings with
idiopathic hyperphosphatasia, which is an autosomal-
recessive bone disease characterized by increased bone
turnover associated with deformities of long bones, kyphosis,
and acetabular protrusion in affected children [30]. A recent
surprising finding is that OPG expression is regulated by
Wnt/β-catenin signaling in osteoblasts, the same pathway
that regulates osteoblastic bone formation [31]. Thus, bone
mass is determined by the combined efforts of osteoblasts
and osteoclasts, and is regulated in osteoblasts by two major
signaling pathways: RANKL/RANK and Wnt/β-catenin.
OPG also appears to protect large blood vessels from medial
calcification, based on the observation of renal and aortic
calcification occurring in OPG knockout mice [32]. Further-
more, the absence of OPG in OPG/apolipoprotein E double
knockout mice accelerates the calcific atherosclerosis that
develops in apolipoprotein E knockout mice, suggesting that
OPG protects against this complication of atherosclerosis
[33]. Whether OPG and RANKL signaling plays important
Available online http://arthritis-research.com/content/9/S1/S1roles in cardiovascular disease remains to be determined and
is controversial [34]. For example, there is also an association
between high levels of OPG in serum and cardiovascular
disease, diabetes, and chronic renal failure in humans [34].
However, OPG in this latter setting does not appear to
protect the skeleton against the increased bone resorption of
secondary hyperparathyroidism mediated by PTH in patients
with renal osteodystrophy or against vascular calcification. It
is possible that OPG in the serum of such patients is bound
to a plasma protein(s) and thus rendered inactive, but further
studies will be required to determine the significance of these
observations, which question whether the RANKL/OPG ratio
in serum is indicative of bone mass/bone resorption in these
settings [35].
Transcription factor activation by
RANKL/RANK in osteoclasts
With the knowledge that RANKL/RANK signaling is essential
for osteoclast formation, major efforts have been made to
identify the signaling pathways that are activated downstream
and to determine the full extent of the involvement of RANKL
in osteoclast biology and common bone diseases. After
RANKL binds to RANK, a key preliminary step in downstream
signaling is binding of TRAFs to specific sites within the
cytoplasmic domain of RANK, which is a transmembrane
protein that - like the TNF receptors - has no intrinsic ability to
activate protein kinases to mediate signaling. TRAF2, -5, and
-6 all bind to RANK, but of these only TRAF6 appears to be
essential in osteoclasts, because only TRAF6 knockout mice
develop osteopetrosis. Interestingly, although two
independently produced mutant TRAF6 mice have osteo-
petrosis, surprisingly one has normal numbers of osteoclasts
(but they are inactive) [36] and the other has no osteoclasts
[37]. At least seven signaling pathways are activated by
RANK-mediated protein kinase signaling; four of them directly
mediate osteoclastogenesis (inhibitor of NF-κB kinase/NF-κB,
c-Jun amino-terminal kinase/activator protein-1, c-myc, and
calcineurin/nuclear factor of activated T cells [NFAT]c1) and
three mediate osteoclast activation (src and MKK6/p38/
MITF) and survival (src and extracellular signal-regulated
kinase). It remains unexplained how inactivation of TRAF6
resulted in two different osteoclast phenotypes, however.
Several adapter molecules bind to RANK along with TRAFs
to mediate signaling. Among these is Grb-2 associated
binder protein 2, a member of a family of adapter molecules
that are phosphorylated at tyrosine residues and recruit a
variety of signaling molecules that contain Src homology 2
domains. Loss of Grb-2 associated binder protein 2 results in
reduced RANKL/RANK-induced osteoclast differentiation,
decreased bone resorption, and mild osteopetrosis. This
indicates that it plays a significant role in RANKL-induced
osteoclastogenesis [38].
The essential role played by NF-κB/activator protein-1/
NFATc1 signaling for osteoclast formation was discovered
after the generation of mice with targeted deletion of both
p50 and p52 subunits of NF-κB and of c-Fos [3], and
following elegant molecular rescue experiments in which
adoptive transfer of Nfatc1-/- hematopoietic stem cells to
Fos-/- mice induced osteoclast formation [39]. Over-
expression of a constitutively active form of NFATc1 induces
osteoclast formation by M-CSF treated Fos-/- or NF-κB
p50/p52-/- osteoclast precursors in the absence of RANKL
[40], indicating that it is downstream from NF-κB and c-Fos
(Figure 1). On the basis of all of these studies, NFATc1 has
been described as the master regulator of osteoclasto-
genesis [39]. It is activated by calcium-dependent calcineurin
dephosphorylation. Cyclosporine A, a calcineurin inhibitor,
inhibits NFATc1 activation, and thus it was surprising that
treatment of patients with this immunosuppressant was
associated with bone loss [41]. The likely explanation for this
effect of cyclosporine A is that NFATc1 also positively
regulates expression of osterix, an essential transcription
factor that regulates osteoblast function [42], and the net
effect is reduced bone formation and osteoporosis [43].
Immunoreceptors, osteoimmunology, and
RANKL
It is not yet clear how calcium signaling is activated during
osteoclast formation, but it appears to involve the Fc receptor
Arthritis Research & Therapy    Vol 9 Suppl 1 Boyce and Xing
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Figure 1
The essential signaling pathway for normal osteoclastogenesis. Under
physiologic conditions, RANKL produced by osteoblasts binds to
RANK on the surface of osteoclast precursors and recruits the adaptor
protein TRAF6, leading to NF-κB activation and translocation to the
nucleus. NF-κB increases c-Fos expression and c-Fos interacts with
NFATc1 to trigger the transcription of osteoclastogenic genes. OPG
inhibits the initiation of the process by binding to RANKL. NFAT,
nuclear factor of activated T cells; NF-κB, nuclear factor-κB; OPG,
osteoprotegerin; RANKL, receptor activator of nuclear factor-κB
ligand; TRAF, tumor necrosis factor receptor associated factor.common  γ subunit (FcRγ) immunoreceptor expressed by
osteoclasts and the adapter protein DNAX-activating protein
12, which associates with an immunoreceptor tyrosine-based
activation motif [44]. DNAX-activating protein 12/FcRγ
double knockout mice have impaired RANKL-induced
NFATc1 activation and osteoclast formation, and are severely
osteopetrotic [45]. However, this receptor-mediated signaling
pathway cannot induce osteoclast formation on its own. Thus,
like M-CSF, it is necessary but not sufficient for osteo-
clastogenesis. FcRγ-associating receptors include osteoclast-
associated receptor, whose expression is regulated by
NFATc1. Thus, signaling through RANKL/RANK and these
receptors in inflammatory disorders provides a NFATc1-
mediated amplifying mechanism that potentially can increase
osteoclast formation beyond that of RANKL alone. This
mechanism for enhanced osteoclast formation in inflam-
matory bone disease can be augmented also by TNF, which
not only induces c-fms expression by OCPs [46] but also
increases proliferation and survival of these cells as well as
enhancing their egress from bone marrow into the
bloodstream, from where they can alight in increased
numbers at sites of inflammation. These OCPs also increase
their production of TNF in response to TNF and RANKL, and
thereby induce an auto-amplifying autocrine vicious cycle to
increase osteoclast numbers. It is likely that osteoclasts and
their precursors secrete many more factors that interact with
immune and other cells to affect bone volume and turnover in
a variety of bone disorders (Figure 2).
Conclusion
The RANKL/RANK/OPG system is one of the most important
discoveries in bone biology in the past decade. This system is
critical for skeletal health, and disruption of it leads to or
causes numerous bone diseases. Recent studies have
indicated that RANKL/RANK signaling also plays an
important role in other tissues (Figure 3).
However, several important issues remain unresolved. For
example, how is this system activated and then inactivated
during normal bone remodeling? Which cells specifically in
the osteoblast/stromal cell lineage regulate normal and
pathologic bone remodeling? Are they all immature, non-
matrix-producing stromal cells or do osteoid synthesizing
osteoblasts play a major regulatory role in addition to keeping
osteoclasts away from them while they are filling in resorption
trenches? Do stromal cells circulate in sufficient numbers,
like OCPs, to play important roles in RANKL/RANK-mediated
normal and pathologic bone remodeling? How does
RANKL/RANK signaling regulate osteoblast function and the
anabolic effects of PTH or other potential anabolic agents?
Do serum levels of RANKL or OPG reflect what is happening
in bone and joints in patients? Does RANKL/RANK signaling
play an important role in cancer cell growth and interaction
with other cells in bone? How exactly do immune cells
influence osteoclast and osteoblast/stromal cell function in
normal and disease states? It is becoming recognized
Available online http://arthritis-research.com/content/9/S1/S1
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Figure 2
Osteoclasts and precursors are secretory cells. In inflammatory bone
disease, systemic elevated TNF stimulates the generation of OCPs in the
bone marrow and also enhances their egress into the bloodstream, from
where they can alight in increased numbers at sites of inflammation.
These OCPs differentiate to osteoclasts and increase their production of
many factors in response to TNF and RANKL and thereby induce an
auto-amplifying autocrine vicious cycle to increase osteoclast numbers
and interact with immune and other cells to affect bone volume and
turnover. OCP, osteoclast precursor; RANKL, receptor activator of
nuclear factor-κB ligand; TNF, tumor necrosis factor.
Figure 3
The role of the RANKL/RANK system in bone and other tissues.
RANKL is produced by a variety of cell types and its expression is
regulated by many physiologic and pathologic factors. Preclinical
studies in mice and studies of human tissues have revealed functions
for RANKL/RANK signaling in normal and pathologic states. OPG can
bind to RANKL and prevent its interaction with RANK to inhibit
osteoclast formation, but its effects on other cellular functions of
RANKL have yet to be determined. OPG, osteoprotegerin; RANKL,
receptor activator of nuclear factor-κB ligand.increasingly that the osteoclast per se - as a secretory cell - is
an immune cell. How important are osteoclasts and their
precursors in regulating their own formation and function
relative to macrophages and other immune cells? Elucidation
of the specific roles played by RANKL/RANK in these various
types of cells will probably link bone remodeling with
regulation of the function of other organ systems in health
and disease.
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